middle.news
Nyrada clears FDA checkpoint for Xolatryp heart-attack trial
8:16am on Tuesday 13th of October, 2026 AEDT
•
Biotechnology
Read Story
Nyrada clears FDA checkpoint for Xolatryp heart-attack trial
8:16am on Tuesday 13th of October, 2026 AEDT
Key Points
FDA found no major issues with Nyrada’s proposed Xolatryp development pathway
Nonclinical safety package appears sufficient to support the planned Phase IIa study
FDA accepted Phase IIa progression before completion of a thorough QT/QTc study
Additional information and stability data are required for the IND submission
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nyrada (ASX:NYR)
OPEN ARTICLE